At the time of writing, 4D Molecular Therapeutics Inc [FDMT] stock is trading at $10.97, up 1.57%. An important factor to consider is whether the stock is rising or falling in short-term value. The FDMT shares have gain 4.38% over the last week, with a monthly amount glided 10.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
4D Molecular Therapeutics Inc [NASDAQ: FDMT] stock has seen the most recent analyst activity on November 07, 2025, when Morgan Stanley upgraded its rating to a Equal-Weight. Previously, BMO Capital Markets downgraded its rating to Market Perform on January 13, 2025, and dropped its price target to $15. On November 21, 2024, Morgan Stanley initiated with a Underweight rating and assigned a price target of $8 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral. Barclays initiated its recommendation with a Overweight and recommended $459 as its price target on April 15, 2024. Barclays started tracking with a Overweight rating for this stock on April 15, 2024, and assigned it a price target of $45.
For the past year, the stock price of 4D Molecular Therapeutics Inc fluctuated between $2.23 and $12.34. Currently, Wall Street analysts expect the stock to reach $25.33 within the next 12 months. 4D Molecular Therapeutics Inc [NASDAQ: FDMT] shares were valued at $10.97 at the most recent close of the market. An investor can expect a potential return of 130.9% based on the average FDMT price forecast.
Analyzing the FDMT fundamentals
According to 4D Molecular Therapeutics Inc [NASDAQ:FDMT], the company’s sales were 0.12M for trailing twelve months, which represents an 2900.00% jump. Gross Profit Margin for this corporation currently stands at -58.47% with Operating Profit Margin at -7679.3%, Pretax Profit Margin comes in at -6972.57%, and Net Profit Margin reading is -6972.57%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.47 and Total Capital is -0.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.63 points at the first support level, and at 10.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.44, and for the 2nd resistance point, it is at 11.90.
Ratios To Look Out For
It is important to note that 4D Molecular Therapeutics Inc [NASDAQ:FDMT] has a current ratio of 8.42. On the other hand, the Quick Ratio is 8.42, and the Cash Ratio is 1.31. Considering the valuation of this stock, the price to sales ratio is 5223.11, the price to book ratio is 1.39.
Transactions by insiders
Recent insider trading involved Bizily Scott, Chief Legal Officer, that happened on Oct 24 ’25 when 2678.0 shares were sold. Officer, SCOTT BIZILY completed a deal on Oct 24 ’25 to buy 1816.0 shares. Meanwhile, Chief Legal Officer Bizily Scott sold 1635.0 shares on Oct 16 ’25.
